Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $49,785.75 in Stock

by · The Markets Daily

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) major shareholder Bioventures 2014 L.P. Mpm sold 57,225 shares of the company’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $0.87, for a total value of $49,785.75. Following the sale, the insider directly owned 4,867,341 shares of the company’s stock, valued at approximately $4,234,586.67. This represents a 1.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

  • On Thursday, December 4th, Bioventures 2014 L.P. Mpm sold 83,230 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total transaction of $80,733.10.
  • On Tuesday, December 2nd, Bioventures 2014 L.P. Mpm sold 59,277 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $52,756.53.
  • On Monday, December 1st, Bioventures 2014 L.P. Mpm sold 60,917 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $57,261.98.
  • On Friday, November 28th, Bioventures 2014 L.P. Mpm sold 20,277 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total transaction of $20,074.23.
  • On Wednesday, November 26th, Bioventures 2014 L.P. Mpm sold 60,733 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $59,518.34.
  • On Tuesday, November 25th, Bioventures 2014 L.P. Mpm sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total value of $39,130.36.
  • On Monday, November 24th, Bioventures 2014 L.P. Mpm sold 88,802 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total transaction of $87,025.96.
  • On Friday, November 21st, Bioventures 2014 L.P. Mpm sold 64,331 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.83, for a total transaction of $53,394.73.
  • On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $36,625.28.
  • On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $62,344.56.

Werewolf Therapeutics Stock Up 8.5%

Shares of Werewolf Therapeutics stock traded up $0.08 during midday trading on Thursday, reaching $1.00. 587,802 shares of the company’s stock traded hands, compared to its average volume of 504,491. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.38. The company’s 50 day simple moving average is $1.42 and its 200 day simple moving average is $1.33. The company has a market cap of $48.36 million, a price-to-earnings ratio of -0.61 and a beta of 0.74.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. Equities analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Charles Schwab Investment Management Inc. raised its stake in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after acquiring an additional 23,852 shares during the last quarter. MPM Asset Management LLC lifted its holdings in Werewolf Therapeutics by 0.6% during the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after buying an additional 25,688 shares in the last quarter. MPM Bioimpact LLC boosted its position in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after buying an additional 20,799 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Werewolf Therapeutics in the 1st quarter valued at $71,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics during the second quarter worth $92,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Bank of America cut their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a report on Wednesday, November 12th. JMP Securities lowered their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Finally, Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Get Our Latest Stock Report on HOWL

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

See Also